SCD gene therapy approaches using CRISPR, gene therapy, and base editing show different stem cell outcomes in a mouse study.

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world applications in medicine and agriculture.